(Total Views: 348)
Posted On: 07/19/2021 9:44:56 PM
Post# of 36554
From the last PR - it looks like FDA approval.
Contingent on FDA approval and the receipt of financing the final vaccine manufacturing process is commercial ready using a lyophilization method that produces a stable, powdered Ii-Key-SARS-CoV-2 vaccine that can potentially be shipped and stored at room temperature, providing a substantial commercial advantage.
Contingent on FDA approval and the receipt of financing the final vaccine manufacturing process is commercial ready using a lyophilization method that produces a stable, powdered Ii-Key-SARS-CoV-2 vaccine that can potentially be shipped and stored at room temperature, providing a substantial commercial advantage.


Scroll down for more posts ▼